Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Shangdong Luoxin Pays $120 Million for China Rights to Lung Cancer Drug

publication date: Aug 1, 2016
Shangdong Luoxin Pharma in-licensed exclusive China rights to a lung cancer drug candidate from South Korea's Yuhan Corp. in a deal potentially worth $120 million in milestones. The drug, YH25448, targets EGFR-mutation positive non-small cell lung cancer in patients resistant to existing therapies. The two pharmas will develop the drug simultaneously in Asia: Luoxin in greater China; Yuhan in Korea and Taiwan. Yuhan received $6 million upfront and is also eligible for double-digit royalties on revenues from Luoxin. More details....

Stock Symbols: (HKSE:8058) (KSE: 000100)

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital